<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>60(6)</volume><submitter>Koyauchi T</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Despite the rapid widespread use of a high-flow nasal cannula (HFNC) during the COVID-19 pandemic, its indications and appropriate use as perceived by physicians remain poorly known.&lt;h4>Methods&lt;/h4>In September 2021, we sent a questionnaire to each respiratory physician from 15 institutions in Shizuoka prefecture, Japan. In this survey, we compared the perceptions of HFNC indications and interventions during implementation to those of non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV). Furthermore, this study examined concerns about SARS-CoV-2 infection spread and psychological distress experienced among respondents.&lt;h4>Results&lt;/h4>Of the 140 respiratory physicians contacted, 87 (62.1%) completed the survey. The results indicate that 96.5% of the respondents agreed with the indication of HFNC for COVID-19, whereas only 13.7% agreed with NIV. The physicians reported that patients with HFNC had a lower frequency of sustained sedation, physical restraint, and implementation in the ICU than that of patients with NIV and IMV. The HFNC was introduced as a respiratory modality following conventional oxygen therapy (COT) in patients with COVID-19, regardless of full or do-not-intubate codes. Additionally, they reported that patients with COVID-19 switched from COT to HFNC significantly earlier than those without COVID-19. Simultaneously, this survey revealed persistent concerns of SARS-CoV-2 infection spread and psychological distress (47.1% and 53.3%, respectively) among respiratory physicians during HFNC use.&lt;h4>Conclusion&lt;/h4>Clinically, HFNC is considered useful for COVID-19 patients by most respiratory physicians. However, HFNC remains a concern for COVID-19 spread and psychological distress among several respiratory physicians, indicating the need for urgent action.</pubmed_abstract><journal>Respiratory investigation</journal><pagination>779-786</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9464591</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical practice of high-flow nasal cannula therapy in COVID-19 pandemic era: a cross-sectional survey of respiratory physicians.</pubmed_title><pmcid>PMC9464591</pmcid><pubmed_authors>Inui N</pubmed_authors><pubmed_authors>Suda T</pubmed_authors><pubmed_authors>Furuhashi K</pubmed_authors><pubmed_authors>Karayama M</pubmed_authors><pubmed_authors>Suzuki Y</pubmed_authors><pubmed_authors>Fujisawa T</pubmed_authors><pubmed_authors>Enomoto N</pubmed_authors><pubmed_authors>Koyauchi T</pubmed_authors><pubmed_authors>Inoue Y</pubmed_authors><pubmed_authors>Hozumi H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical practice of high-flow nasal cannula therapy in COVID-19 pandemic era: a cross-sectional survey of respiratory physicians.</name><description>&lt;h4>Background&lt;/h4>Despite the rapid widespread use of a high-flow nasal cannula (HFNC) during the COVID-19 pandemic, its indications and appropriate use as perceived by physicians remain poorly known.&lt;h4>Methods&lt;/h4>In September 2021, we sent a questionnaire to each respiratory physician from 15 institutions in Shizuoka prefecture, Japan. In this survey, we compared the perceptions of HFNC indications and interventions during implementation to those of non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV). Furthermore, this study examined concerns about SARS-CoV-2 infection spread and psychological distress experienced among respondents.&lt;h4>Results&lt;/h4>Of the 140 respiratory physicians contacted, 87 (62.1%) completed the survey. The results indicate that 96.5% of the respondents agreed with the indication of HFNC for COVID-19, whereas only 13.7% agreed with NIV. The physicians reported that patients with HFNC had a lower frequency of sustained sedation, physical restraint, and implementation in the ICU than that of patients with NIV and IMV. The HFNC was introduced as a respiratory modality following conventional oxygen therapy (COT) in patients with COVID-19, regardless of full or do-not-intubate codes. Additionally, they reported that patients with COVID-19 switched from COT to HFNC significantly earlier than those without COVID-19. Simultaneously, this survey revealed persistent concerns of SARS-CoV-2 infection spread and psychological distress (47.1% and 53.3%, respectively) among respiratory physicians during HFNC use.&lt;h4>Conclusion&lt;/h4>Clinically, HFNC is considered useful for COVID-19 patients by most respiratory physicians. However, HFNC remains a concern for COVID-19 spread and psychological distress among several respiratory physicians, indicating the need for urgent action.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-21T23:34:44.725Z</modification><creation>2025-02-18T23:58:19.576Z</creation></dates><accession>S-EPMC9464591</accession><cross_references><pubmed>36153288</pubmed><doi>10.1016/j.resinv.2022.08.007</doi></cross_references></HashMap>